Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 803.52

-1.1%

3:13 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Miljenko Zuanic	2/12/2008 2:28:25 AM
	of 3559

From Sanofi PR, en.sanofi-aventis.com "Oncology The database lock for the phase III study evaluating aflibercept (VEGF Trap, alliance with Regeneron) as a thirdline treatment for advanced ovarian cancer is due to be completed in the second quarter of 2008. Aflibercept has a novel mechanism of action and its properties, as compared with monoclonal antibodies, give it the potential to be a more powerful anti-angiogenesis agent with a broader spectrum of activity." Observation: Are they combining PII ovarian and PII/III ascite into "PIII study"? No note for target date: "filing for approval", so they are not as optimistic as early 2007. "Enrolment has started in 4 pivotal phase III studies: - first-line treatment of hormone refractory prostate cancer (in association with Taxotere®/prednisone); - second-line treatment of colorectal cancer (in association with the FOLFIRI regimen); - second-line treatment of non small cell lung cancer (in association with Taxotere®); - first-line treatment of pancreatic cancer (in association with gemcitabine)."

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next